09/08/2026
A new lawsuit by Humana adds another layer of complexity to the proposed nationwide Roundup settlement.
Humana has sued Bayer and Monsanto in federal court, alleging that it paid medical expenses for Medicare Advantage members diagnosed with non-Hodgkin lymphoma after alleged Roundup exposure. The insurer seeks reimbursement and alleges that the proposed settlement does not provide an adequate method for resolving its claims. It is also seeking double damages under the Medicare Secondary Payer Act.
The dispute comes as Bayer seeks final approval of a proposed $7.25 billion nationwide settlement for current and future Roundup claims alleging non-Hodgkin lymphoma injuries. Bayer has said the program would be funded through capped payments over up to 21 years, subject to court approval.
For law firms and mass-tort operators, the development highlights a critical reality of large-scale settlement administration:
A claimant’s gross settlement amount is not necessarily the final amount they receive.
Medical liens, Medicare-related obligations, health-plan reimbursement claims, and settlement-administration procedures can all affect the path from settlement approval to net recovery.
The proposed settlement’s final approval hearing is currently scheduled for September 14. How the court addresses settlement mechanics, lien resolution, and third-party reimbursement claims may be important to watch in the weeks ahead.